<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03887715</url>
  </required_header>
  <id_info>
    <org_study_id>LND-300</org_study_id>
    <nct_id>NCT03887715</nct_id>
  </id_info>
  <brief_title>A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression</brief_title>
  <acronym>RECOVER</acronym>
  <official_title>A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LivaNova</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LivaNova</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives of this study are to determine whether active VNS Therapy treatment is superior to
      a no stimulation control in producing a reduction in baseline depressive symptom severity,
      based on multiple depression scale assessment tools at 12 months from randomization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, multi-center, randomized, controlled, blinded trial of subjects implanted with
      VNS Therapy. Active treatment and no stimulation control are randomized, at least two weeks
      after implantation and observed for 12-months.

      After completing the 12 month endpoint in the RCT portion of the study, all RECOVER subjects
      will transition into the prospective, open-label, longitudinal portion of the study. Subjects
      in the control arm of RECOVER will be activated after completing the 12 month endpoint.

      After completion of enrollment in the RCT portion or meeting of interim success criterion
      (whichever comes first), up to 5,800 new subjects may enroll directly into the
      open-label,prospective, longitudinal study. These subjects will participate in the study for
      approximately 5 years.

      The study has been designed in accordance with The Centers for Medicare and Medicaid Services
      coverage with evidence development (CED) decision entitled &quot;Decision Memo for Vagus Nerve
      Stimulation (VNS) for Treatment Resistant Depression (TRD) (CAG-00313R2).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 26, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2030</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1:1 randomization of active stimulation vs. no stimulation for 12 months post randomization.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Central Rater and sponsor are blinded in the RCT phase. Sites will need to have an unblinded programmer who is only programming the device and not collecting outcomes data.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery Åsberg Depression Rating Scale (MADRS) Rate of Response</measure>
    <time_frame>12 months post randomization</time_frame>
    <description>The rate of response defined as person months of response/total months of study participation where response is at least a 50% reduction from baseline in MADRS total score. Subjects discontinuing the study before the endpoint assessment will be considered as non-responders for each successive month after discontinuance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Montgomery Åsberg Depression Rating Scale (MADRS) Time to First response</measure>
    <time_frame>Baseline up to 12 Months</time_frame>
    <description>Time from randomization to the first observed MADRS response.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Montgomery Åsberg Depression Rating Scale (MADRS) Time to First Remission</measure>
    <time_frame>Baseline up to 12 Months</time_frame>
    <description>Time from randomization to the first observed MADRS remission.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Montgomery Åsberg Depression Rating Scale (MADRS) Duration of Response</measure>
    <time_frame>Baseline up to 12 Months</time_frame>
    <description>Duration of MADRS response, defined as the number of consecutive months from first observed MADRS response to the first assessment of MADRS response relapse.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Montgomery Åsberg Depression Rating Scale (MADRS) Rate of Remission</measure>
    <time_frame>Baseline up to 12 Months</time_frame>
    <description>The rate of remission is defined as total number of months in remission divided by total months of expected study participation. Subjects discontinuing the study before the endpoint assessment will be considered as non-in-remission for each successive month after discontinuance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Montgomery Åsberg Depression Rating Scale (MADRS) Maximum duration of Response</measure>
    <time_frame>Baseline up to 12 Months</time_frame>
    <description>Maximum duration of MADRS response, defined as the maximum number of consecutive months in response (only for subjects experiencing MADRS response).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Montgomery Åsberg Depression Rating Scale (MADRS) Duration of Remission</measure>
    <time_frame>Baseline up to 12 Months</time_frame>
    <description>Duration of MADRS remission, defined as the number of consecutive months from first observed MADRS remission to the first assessment of MADRS remission relapse (defined score &gt; 20).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Montgomery Åsberg Depression Rating Scale (MADRS) Maximum duration of Remission</measure>
    <time_frame>Baseline up to 12 Months</time_frame>
    <description>Maximum duration of MADRS remission, defined as the maximum number of consecutive months in remission (only for subjects experiencing MADRS remission).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess all Adverse Events</measure>
    <time_frame>Implant to 12 Months</time_frame>
    <description>All adverse events, with a focus on device or procedure-related serious adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>WHO Disability Assessment Schedule (WHODAS) Changes in scores over time</measure>
    <time_frame>Baseline to 12 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Health Outcome Scale (EQ-5D-L) Changes in scores over time</measure>
    <time_frame>Baseline to 12 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Global Impressions Scale - Improvement (CGI-I) Response</measure>
    <time_frame>12 months post randomization</time_frame>
    <description>A CGI-I score ≤ 2 at 12 months from randomization. Subjects discontinuing the study before the 12 months assessment will be considered as not in response for each successive month after discontinuance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sheehan Suicidality Tracking Scale (S-STS) Changes in Suicidality</measure>
    <time_frame>Implant to 12 Months</time_frame>
    <description>Suicide attempts as measured by items #10 &amp; #12 in S-STS scale</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">6800</enrollment>
  <condition>Treatment Resistant Depression</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group will have VNS activated 2 weeks post implant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Group will be implanted with VNS but device is not activated for the first 12 months. After 12 months, this group can receive stimulation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vagus Nerve Stimulation (VNS)</intervention_name>
    <description>VNS is an implantable device that delivers stimulation to the vagal nerve.</description>
    <arm_group_label>Active</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <other_name>VNS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The patient must be in a major depressive disorder (MDD) episode for ≥ two years or have
        had at least four episodes of MDD, including the current episode.

        The patient's depressive illness meets a minimum criterion of four prior failed treatments
        of adequate dose and duration as measured by a tool designed for this purpose.

        The patient is experiencing a major depressive episode (MDE) as measured by a guideline
        recommended depression scale assessment tool on two visits, within a 45-day span prior to
        implantation of the VNS device.

        Patients must maintain a stable medication regimen for at least four weeks before device
        implantation.

        Exclusion Criteria:

        Current or lifetime history of psychotic features in any MDE;

        Current or lifetime history of schizophrenia or schizoaffective disorder;

        Current or lifetime history of any other psychotic disorder;

        Current or lifetime history of rapid cycling bipolar disorder;

        Current secondary diagnosis of delirium, dementia, amnesia, or other cognitive disorder;

        Current suicidal intent; or

        Treatment with another investigational device or investigational drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Conway, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Yates, BSN</last_name>
    <phone>281-228-7433</phone>
    <email>laura.yates@livanova.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeff Way, BS</last_name>
    <phone>281-228-7394</phone>
    <email>jeffrey.way@livanova.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CMB Clinical Trials</name>
      <address>
        <city>Colton</city>
        <state>California</state>
        <zip>92324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jitendra Verma</last_name>
      <phone>909-423-0367</phone>
      <email>jverma@cmbct.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ATP Clinical Research, Inc.</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92626</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bobby Shih</last_name>
      <phone>714-277-4472</phone>
      <email>bshih@atpcr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Syrentis Clinical Research</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Barber</last_name>
      <phone>714-542-3008</phone>
      <phone_ext>308</phone_ext>
      <email>JBarber@syrentis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medycal Research, Inc</name>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <zip>34609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Waqar Mian</last_name>
      <phone>989-671-7119</phone>
      <email>research.coordinator@medycalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galiz Research LLC</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yohana Lima</last_name>
      <phone>305-805-0921</phone>
      <email>yohana@galizresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clintex Research Group, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raul Pardo</last_name>
      <phone>305-597-3929</phone>
      <email>rpardo@clintexresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Center Of Florida, Inc</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damian Beltran-Garces</last_name>
      <phone>305-603-8844</phone>
      <email>dgarces@doctor.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>APG Research, LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaley Kildahl</last_name>
      <phone>407-808-1875</phone>
      <email>kaleyapg@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Millenia Psychiatry &amp; Research, Inc</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32819</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Santosh Pillai, MD</last_name>
      <phone>407-830-0414</phone>
      <email>santoshpillaido@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Quantum Laboratories Inc.</name>
      <address>
        <city>Pompano Beach</city>
        <state>Florida</state>
        <zip>33064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Herr, MD</last_name>
      <phone>954-933-2324</phone>
      <email>quantumres2@quantum-lab.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced Mental Health Care Inc.</name>
      <address>
        <city>Royal Palm Beach</city>
        <state>Florida</state>
        <zip>33411</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elyssa Sisko</last_name>
      <phone>561-333-8884</phone>
      <email>Amhc.phones@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IACT Health</name>
      <address>
        <city>Grayson</city>
        <state>Georgia</state>
        <zip>30017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhammed Ahmed, M.D.</last_name>
      <phone>678-798-2153</phone>
      <email>mahmed@iacthealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Psych Atlanta</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Kane</last_name>
      <phone>770-422-2846</phone>
      <email>jenniferk@nbmedicine.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pearl Health Clinic</name>
      <address>
        <city>Ammon</city>
        <state>Idaho</state>
        <zip>83406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Knutson</last_name>
      <phone>208-346-7500</phone>
      <phone_ext>300</phone_ext>
      <email>jknutson@pearlhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Joliet Center For Clinical Research</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <zip>60435</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cosme Lozano, MD</last_name>
      <phone>815-729-7790</phone>
      <email>cosme.lozano@jolietcenter.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AMR- Baber Research, Inc.</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60563</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Freeda Baber</last_name>
      <phone>603-272-4844</phone>
      <email>freeda@baberresearchgroup.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Psychiatric Medicine Associates, LLC</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60076</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda White</last_name>
      <phone>847-679-8000</phone>
      <phone_ext>12</phone_ext>
      <email>awhite.pma@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neuroscience Research Institute</name>
      <address>
        <city>Winfield</city>
        <state>Illinois</state>
        <zip>60910</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danesh Alam, MD</last_name>
      <phone>708-686-0000</phone>
      <email>dalam@neuroscienceresearchinstitute.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sheppard Pratt Health System, Inc.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittany Troen</last_name>
      <phone>410-938-3139</phone>
      <email>btroen@sheppardpratt.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Insights</name>
      <address>
        <city>Glen Burnie</city>
        <state>Maryland</state>
        <zip>21061</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norhan Ibrahim</last_name>
      <phone>410-768-9072</phone>
      <email>ibrahim@clinicalinsights.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megha Nagaswami</last_name>
      <phone>617-724-7244</phone>
      <email>MNAGASWAMI@mgh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Michigan Clinical Research Institute PC</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zach Sila</last_name>
      <phone>734-834-8954</phone>
      <email>zachsila@umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>PsychCare Consultants Research</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Broeker</last_name>
      <phone>314-849-1853</phone>
      <phone_ext>203</phone_ext>
      <email>anita.broeker@pccresearch.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alivation Research, LLC</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Espenschade</last_name>
      <phone>402-817-2235</phone>
      <email>KEspenschade@alivation.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erie County Medical Center/State University of New York (SUNY) at Buffalo Affiliate</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sevie Kandefer</last_name>
      <phone>716-898-4038</phone>
      <email>sk293@buffalo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hapworth Research Inc.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariah Garcia</last_name>
      <phone>212-956-2000</phone>
      <email>mgarcia@treatmentonline.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Richmond Behavioral Associates</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10312</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Smith, PhD</last_name>
      <phone>718-317-5522</phone>
      <phone_ext>301</phone_ext>
      <email>smith@rbany.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Science</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Barbara Lasater</last_name>
      <phone>336-716-5348</phone>
      <email>blasater@wakehealth.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NPC Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73109-3834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Poole</last_name>
      <phone>405-634-5529</phone>
      <email>Jlp.nprc@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rivus Wellness &amp; Research Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marvin Peyton, MD</last_name>
      <phone>405-753-4994</phone>
      <email>drpeyton@rivusinstitute.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morgan Dancy</last_name>
      <phone>843-876-5141</phone>
      <email>maddoxm@musc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neuropsychiatric Associates, Plc</name>
      <address>
        <city>Woodstock</city>
        <state>Vermont</state>
        <zip>05091</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Shaw</last_name>
      <phone>802-457-4904</phone>
      <email>sshaw@woodstockresearch.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center For Anxiety and Depression</name>
      <address>
        <city>Mercer Island</city>
        <state>Washington</state>
        <zip>98040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David L Dunner, MD</last_name>
      <phone>206-230-0330</phone>
      <email>dldunner@comcast.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seattle Neuropsychiatric Treatment Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Allen, MD</last_name>
      <phone>206-467-6300</phone>
      <email>rebecca.allen@seattlentc.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=292</url>
    <description>CMS Decision Memo for Vagus Nerve Stimulation (VNS) for Treatment Resistant Depression</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 21, 2019</study_first_submitted>
  <study_first_submitted_qc>March 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2019</study_first_posted>
  <last_update_submitted>May 21, 2020</last_update_submitted>
  <last_update_submitted_qc>May 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VNS</keyword>
  <keyword>Depression</keyword>
  <keyword>TRD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

